The Phase IIA trial is focused on assessing the safety and efficacy of the oral insulin capsule on 10 type 2 diabetes patients. This study is a continuation of the recently successfully completed Phase I studies in Israel.
Nadav Kidron, CEO of Oramed Pharmaceuticals, said: “We have had much success with our past clinical trials, and are on schedule with reaching our planned milestones and hope that Oramed’s oral insulin capsule will succeed in revolutionizing the current treatment for diabetes.”